Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: Impact of length of cycles

Supportive Care in Cancer

Volumn 10, Issue 3, 2002, Pages 222-230

  Genre, D ^a   Protiere C ^b   Macquart Moulin, G ^a   Gravis, G ^a   Camerlo, J ^a   Alzieu, C ^a   Maraninchi, D ^a,c   J P Moatti, ^b,c   Viens, P ^a,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Breast cancer; Chemotherapy; Dose intensity; Quality of life; Side effect

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONJUNCTIVITIS; CYSTITIS; DIARRHEA; DISTRESS SYNDROME; DRUG MEGADOSE; FATIGUE; FEVER; HEADACHE; HOT FLUSH; HUMAN; MYALGIA; NAUSEA AND VOMITING; PAIN; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SELF REPORT; STOMACH PAIN; SYMPTOMATOLOGY; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ALOPECIA; ANOREXIA; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; QUALITY OF LIFE;

EID: 0036940707     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-001-0322-3     Document Type: Article

References (39)

1. Aaronson NK, Ahmedzai S, Bergman B, et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376
2. Bernhard J, Gusset H, Hürny C (1998) Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research. Stat Med 17:633-639
3. Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn HJ, Rudenstam CM for the International Breast Cancer Study Group (IBCSG) (1997) Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. Ann Oncol 8:825-835
4. Bernhard J, Sullivan M, Hurny C, Coates AS, Rudenstam CM (2001) Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 84:1156-1165
5. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15
6. Cohen J (1968) Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 70:213-220
7. Cohen J (1988) Statistical power analysis for the behavorial sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale NJ
8. Da Silva FC, Fossa SD, Aaronson NK, et al (1996) The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer [A] 32:72-77
9. Fisher B, Anderson S, Wickerham DL, et al (1997) Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869
10. Grossman SA, Sheidler VR, Swedeen K, et al (1991) Correlation of patient and caregivers ratings of cancer pain. J Pain Symptom Manage 6:53-57
11. Hjermstad JM, Fossa SF, Bjordal K, et al. (1995) Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 13:1249-1254
12. Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 2:1281-1288
13. Hryniuk W, Frei E III, Wright FA (1998) A single scale for comparing dose intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity. J Clin Oncol 16:3137-3147
14. Hürny C, Bernhard J, Coates A, Peterson HF, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Collins J, Senn HJ (1996) Responsiveness of a single-item indicator versus a multi-item scale. Assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care 34:234-248
15. Huskisson EC (1974) Measurement of pain. Lancet II:1127-1131
16. Jones RB, Holland JF, Bhardwaj S, et al (1987) A phase I-II study of intensive-dose Adriamycin for advanced breast cancer. J Clin Oncol 5:172-177
17. Klee MC, King MT, Machin D, Hansen HH (2000) A clinical model for quality of life assessment in cancer patients receiving chemotherapy. Ann Oncol 11:23-30
18. Lalisang RI, Voest EE, Wils JA, et al (2000) Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer. Br J Cancer 82:1914-1919
19. Landis RJ, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-174
20. Larsen J, Gardulf A, Nordström G, et al (1996) Health-related quality of life in women with breast cancer undergoing autologous stem-cell transplantation. Cancer Nurs 19:368-375
21. Lichtman SM, Ratain MJ, Van Echo DA, et al (1993) Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst 85:1319-1326
22. Love RR, Leventhal H, Easterling DV, et al (1989) Side effects and emotional distress during cancer chemotherapy. Cancer 63:604-612
23. Macquart-Moulin G, Viens P, Genre D, et al (1997) Discordance between physicians' estimations and breast cancer patients' self assessment of side-effects of chemotherapy: an issue for quality of care. Br J Cancer 76:1640-1645
24. Macquart-Moulin G, Viens P, Genre D, et al (1999) Concomitant chemoradiotherapy for nonmetastatic breast carcinoma: side-effects, quality of life, and daily organization. Cancer 85:2190-2199
25. Macquart-Moulin G, Viens P, Palangié T, et al (2000) High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol 18:754-764
26. McLachlan SA, Devins GM, Goodwin PJ (1998) Validation of the European Organization for Research and Treatment of Cancer quality of life questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. Eur J Cancer 34:510-517
27. Niezgoda HE, Pater JL (1993) A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res 2:319-325
28. Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12:608-616
29. Osoba D (1996) Rationale for the timing of health-related quality of life (HQL) assessments in oncological palliative therapy. Cancer Treat Rev 22 [Suppl A]:69-73
30. Osoba D, Zee B, Pater J, et al (1994) Psychometrics properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364
31. Pater J, Osoba D, Zee B, et al (1998) Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. Qual Life Res 7:273-278
32. Sneeuw KCA, Aaronson NK, Sprangers MAG, et al (1997) Values of caregivers ratings in evaluating the quality of life of patients with cancer. J Clin Oncol 15:1206-1217
33. Sneeuw KCA, Aaronson NK, Sprangers MAG, et al (1999) Evaluating the quality of life of cancer patients: assessments by patient, significant others, physicians and nurses. Br J Cancer 81:87-94
34. Sprangers MAG, Aaronson NK (1992) The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 45:743-760
35. SPSS (1993) SPSS-X users' guide (release 6.0). SPSS, Cary, NC
36. Stephens RJ, Hopwood P, Girling DJ, et al (1997) Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 6:225-236
37. Swain SM, Rowland J, Weinfurt K, et al (1996) Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. J Clin Oncol 14:1565-1572
38. Twelves CJ, Ramirez AJ, Richards MA, et al (1990) A comparison of response, survival and quality of life (QoL) using 2 doxorubicin (Dox) schedules of equal dose intensity in metastatic breast cancer (abstract). Br J Cancer 62:498-499
39. Wood WC, Budman DR, Korzun AH, et al (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259